Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,

Slides:



Advertisements
Similar presentations
Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Advertisements

Presenter Disclosure Information
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Between May 2013 and June 2014, we implanted the C-Pulse device in 7 male and 1 female patients with a mean age ± SD of 61.1 ± 9.4 years. Four had ischemic.
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Treatment of Heart Failure: Beyond Medical Therapy
Indication and contra-indications for cardiac catheterization
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
1 Investigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU – ESC 2012 European Society of Cardiology Congress 2012 Munich,
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
1 Chronic Treatment of Resistant Hypertension with an Implantable Medical Device: Interim 3 Year Results of Two Studies of the Rheos ® Hypertension System.
Clinical Symptoms of Atrial Fibrillation in Different Ranges of QRS Duration Burda I.Yu., Yabluchansky N.I. Medical Clinics Chair National University of.
Case Studies The results presented in these case studies are specific to these individual patients. Patient results will vary, not every response is the.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
In the name of GOD 1. Treatment of End Stage Heart Failure Surgical Treatments Cardiac Resynchronization Treatment(CRT) 2.
Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Natural History of Heart Failure
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
Transcatheter Cardiovascular Therapeutics 2008 (October 12-17, 2008 · Washington, DC) First-in-Human Report: Initial Experience with a Stentless and Retrievable.
BACKGROUND Refractory angina The balloon expandable, stainless steel, hourglass-shaped, coronary-sinus reducing device creates a focal narrowing and increases.
mild Decompression for the Treatment of Lumbar Spinal Stenosis
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
METHODS The EASYTRAK 2 lead was studied along with the CONTAK  RENEWAL  2/4/4HE device in the Device Evaluation of the CONTAK RENEWAL 2/4/4HE with EASYTRAK.
Total Occlusion Study of Canada (TOSCA-2) Trial
Extending the Boundaries of TAVR: Future Directions
David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
University of Pennsylvania Philadelphia
Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.
The CARILLON: Device Iteration, New Data and New Trials
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
University of Pennsylvania
Giuseppe Tarantini MD, PhD
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Cardiovacular Research Technologies
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Study Design Patients with LBBB and LV dysfunction
Sildenafil for Improving Outcomes in Patients With Corrected Valvular Heart Disease and Persistent Pulmonary Hypertension: A Multicenter, Double-Blind,
Presentation transcript:

Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz, Cardiocentrum Berlin, Berlin, Germany; Jan Schmitto, Hannover Medical Sch, Hannover, Germany; Mirko Seidel, Unfallkrankenhaus Berlin, Berlin, Germany; Thomas Krabatsch, Deutsches Herzzentrum Berlin, Berlin, Germany American Heart Association Meeting American Heart Association meeting - November 20141

Disclosures H. Hotz: None A.Schulz: None J. Schmitto: None M. Seidel: None T. Krabatsch: None American Heart Association meeting - November 20142

Sunshine Heart, Inc. is sponsoring the OPTIONS HF Clinical Trial. It is a post market, multi-center surveillance study with up to 15 centers participating throughout Europe. Up to 50 patients will be implanted in the study and be followed up to 5 years. OPTIONS HF Clinical Study X Ascending aortic calcification or CABG X Mitral Valve Incompetence, Grade 4+ X Aortic Valve Incompetence, Grade X Patient has systolic blood pressure less than 90 or greater than 140 mm Hg √NYHA Class III and Ambulatory Class IV √ On optimal medical therapy and remains symptomatic √ Had been evaluated for or have CRT or CRT-D therapy and remain symptomatic or ICD therapy (narrow QRS) √ 6MHW m √ At least one hospitalization for decompensated HF, while on HF medications, OR BNP level > 300 or NTproBNP > 1500 within 12 months prior to randomization √ Both ischemic and non-ischemic Key Study Qualifications: Study Objective: The study is designed to observe the clinical outcomes of heart failure patients treated with the C-Pulse® System in the usual manner and according to the approved indications and contraindications. American Heart Association meeting - November 20143

A minimally invasive, non-blood contacting, counter- pulsation heart assist therapy for the treatment of moderate to severe heart failure. Reduce LV work, increase flow Balloon inflates – increases coronary perfusion (addresses hemodynamics - primary pathophysiology of heart failure) Balloon deflates – decrease afterload Minimally invasive procedure can be performed in 90 minutes No blood contact – lower likelihood of clot or stroke Ability to disconnect – patient comfort and convenience The C-Pulse® System Extra-Aortic Cuff ECG Sensing Lead Driver Percutaneous Interface Lead American Heart Association meeting - November 20144

All Patients (N=8) Mean ±SD (range) Age (in years)60.8 ± 10.5 (51, 79) Gender Male87.5% (7/8) Female12.5% (1/8) Co-morbidities Arrhythmia50% (4/8) Diabetes Mellitus62.5% (5/8) Smoking history87.5% (7/8) Cardiomyopathy100% (8/8) - Ischemic50% (4/8) - Non-Ischemic50% (4/8) INTERMACS Profile 4: Resting symptoms37.5% (3/8) 5: Exertion Intolerant37.5% (3/8) 6: Exertion Limited25% (2/8) NYHA Class III87.5% (7/8) IV12.5% (1/8) CRT62.5% (5/8) ICD Therapy75.0% (6/8) Methods American Heart Association meeting - November 20145

8/8 (100%) of patients successfully implanted No procedural device-related complications CPB used in 1 patient with concomitant CABG No stroke, myocardial infarction, major bleeding or major infection were reported due to the device through 6 months One patient was weaned off the device after 6 months of support and showed an increase in EF from 20% at baseline to 44% at 6-months One patient developed non-device related refractory tachycardia with worsening heart failure 12 hours after surgery which prevented C-Pulse from supporting the heart properly resulting in subsequent VAD implant 5 days after the index procedure Results American Heart Association meeting - November 20146

Baseline N=4 6 months N=4 Results: NYHA – 6 Months American Heart Association meeting - November 20147

Baseline N=4 6 months N= ± 77 Results: 6MWT – 6 Months ± 25 American Heart Association meeting - November 20148

Results: LVEF (%) – 6 Months American Heart Association meeting - November 20149

Conclusion Preliminary results from this small cohort in the European Option HF post-market study demonstrate safety of implantation of the C-Pulse System 6 month results show improvements in functional capacity and physician assessed functional status Efficacy also demonstrated in cardiac remodeling C-Pulse Heart Assist System is a promising therapeutic option for patients with moderate to severe heart failure American Heart Association meeting - November